Clinical trials: ADHD - Attention Deficit Disorder With Hyperactivity
- Condition ADHD - Attention Deficit Disorder With Hyperactivity
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to <12 years with ADHD.
- Trial name
- NCT07717879
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 30 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.
- Trial name
- NCT07717892
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 28 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.
- Trial name
- NCT07773883
- Testing
- Solriamfetol
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Effects of Probiotics on the Gut-brain Axis in Children
The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.
- Trial name
- NCT07459699
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Probi AB
Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder
A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD
- Trial name
- AK-D101_BS (NCT07678827)
- Testing
- AK-D101
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Alvogen Korea
ADHD
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with…
- Trial name
- NCT06359899
- Testing
- AK0901 capsule
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.
- Trial name
- NCT07217977
- Testing
- observational study
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Qbtech AB
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD)
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as…
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Trial name
- NCT07220330
- Testing
- QbMobile
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Qbtech AB
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05924594
- Testing
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
tRNS Treatment for ADHD Symptoms
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD.
- Trial name
- NCT06189703
- Testing
- tRNS
- Where
- 5 sites in United States, Israel
- Volunteers
- 146 people
- Sponsor
- Innosphere
Attention Deficit Disorder With Hyperactivity (ADHD)
Healing Minds II: Biofeedback, Breathing Practices, Nutrition and Exercise Counseling in Children and Adolescents With ADHD
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling.
- Trial name
- NCT07180602
- Testing
- Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
- Where
- United States
- Sponsor
- Hoskinson Health and Wellness Clinic
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention-Deficit/Hyperactivity Disorder (ADHD)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
- Trial name
- ADHD (NCT06215144)
- Testing
- NRCT-101SR
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Neurocentria, Inc.
ADHD
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
- Trial name
- NCT06673368
- Testing
- NRCT-101SR, NRCT-202XR
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Neurocentria, Inc.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.
- Trial name
- NCT07087327
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.